Daron Evans

Insider Reports History

Location: South Orange, NJ
Owner filing signature: /s/ Daron Evans
Transaction evidence: Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Daron Evans

Form 4 holding CFO

Rezolute, Inc.

Security class: Common Shares
Shares / value: 414,462
Estimated value: $1,181,216
Report date: 30 Mar 2026
Price: $2.85
Ownership: Direct

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock
Shares / value: 134,215
Estimated value: $295,622
Report date: 24 May 2021
Price: $2.20
Ownership: Direct

Form 4 holding CFO

Rezolute, Inc.

Security class: Common Shares
Shares / value: 40,000
Estimated value: $94,400
Report date: 30 Mar 2026
Price: $2.36
Ownership: Held by PoC Capital LLC

Form 4 holding CFO

Rezolute, Inc.

Security class: Common Shares
Shares / value: 23,000
Estimated value: $54,280
Report date: 30 Mar 2026
Price: $2.36
Ownership: Held by minor child #1

Form 4 holding CFO

Rezolute, Inc.

Security class: Common Shares
Shares / value: 20,000
Estimated value: $47,200
Report date: 30 Mar 2026
Price: $2.36
Ownership: Held by spouse

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock
Shares / value: 8,947
Estimated value: $19,707
Report date: 27 May 2021
Price: $2.20
Ownership: By UTMA #1

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock
Shares / value: 8,669
Estimated value: $19,094
Report date: 27 May 2021
Price: $2.20
Ownership: By UTMA #2

Form 4 holding CFO

Rezolute, Inc.

Security class: Common Shares
Shares / value: 7,000
Estimated value: $16,520
Report date: 30 Mar 2026
Price: $2.36
Ownership: Held by minor child #2

Form 4 holding CFO

Rezolute, Inc.

Security class: Common Shares
Shares / value: 7,000
Estimated value: $16,520
Report date: 30 Mar 2026
Price: $2.36
Ownership: Held by minor child #3

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock
Shares / value: 6,111
Estimated value: $13,460
Report date: 24 May 2021
Price: $2.20
Ownership: By PoC Capital, LLC

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock
Shares / value: 888
Estimated value: $1,956
Report date: 24 May 2021
Price: $2.20
Ownership: By UTMA #3

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock
Shares / value: 888
Estimated value: $1,956
Report date: 24 May 2021
Price: $2.20
Ownership: By UTMA #4

Form 4 holding CFO

Rezolute, Inc.

Security class: Employee Stock Option (Right to Buy)
Shares / value: 63,000
Estimated value
Report date: 19 Nov 2025
Price
Ownership: Direct
Underlying class: Common Shares
Underlying amount

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Stock Option (Right to Buy)
Shares / value: 20,000
Estimated value
Report date: 24 May 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock Warrants (Right to Buy)
Shares / value: 0
Estimated value
Report date: 24 May 2021
Price
Ownership: By UTMA #1
Underlying class: Common Stock
Underlying amount

Form 4 holding CEO Specialty Renal Products

NEPHROS INC

Security class: Common Stock Warrants (Right to Buy)
Shares / value: 0
Estimated value
Report date: 24 May 2021
Price
Ownership: By UTMA #2
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Daron Evans

4 RZLT

Rezolute, Inc.

Report period: 30 Mar 2026
Transactions: 1
Transaction value: +$28,500
Accepted by SEC: 31 Mar 2026, 16:59
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 02 Mar 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Mar 2026, 18:16
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 15 Dec 2025
Transactions: 3
Transaction value: +$79,578
Accepted by SEC: 15 Dec 2025, 19:35
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 19 Nov 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 21 Nov 2025, 17:31
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 24 Jun 2025
Transactions: 1
Transaction value: +$20,250
Accepted by SEC: 24 Jun 2025, 12:41
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 10 Jun 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 12 Jun 2025, 21:29
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 26 Mar 2025
Transactions: 2
Transaction value: +$57,700
Accepted by SEC: 28 Mar 2025, 08:40
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 16 Feb 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 19 Feb 2025, 21:29
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 18 Dec 2024
Transactions: 1
Transaction value: +$42,900
Accepted by SEC: 18 Dec 2024, 18:01
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 12 Dec 2024
Transactions: 1
Transaction value: +$41,400
Accepted by SEC: 12 Dec 2024, 16:54
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 09 Dec 2024
Transactions: 1
Transaction value: +$53,167
Accepted by SEC: 10 Dec 2024, 09:11
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 23 Sep 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 24 Sep 2024, 13:03
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 14 Jun 2024
Transactions: 1
Transaction value: +$161,568
Accepted by SEC: 14 Jun 2024, 12:06
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 29 May 2024
Transactions: 1
Transaction value: +$1,578
Accepted by SEC: 31 May 2024, 16:05
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 23 May 2024
Transactions: 2
Transaction value: +$9,668
Accepted by SEC: 28 May 2024, 14:48
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 15 Mar 2024
Transactions: 1
Transaction value: +$33,830
Accepted by SEC: 19 Mar 2024, 09:17
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 08 Mar 2024
Transactions: 1
Transaction value: +$96,345
Accepted by SEC: 08 Mar 2024, 12:37
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 16 Feb 2024
Transactions: 3
Transaction value: +$66,741
Accepted by SEC: 20 Feb 2024, 07:01
Role: CFO
Next action: Open filing details

4 RZLT

Rezolute, Inc.

Report period: 23 Jan 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 25 Jan 2024, 12:47
Role: CFO
Next action: Open filing details

3 RZLT

Rezolute, Inc.

Report period: 22 Jan 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 25 Jan 2024, 12:46
Role: CFO
Next action: Open filing details

4/A NEPH

NEPHROS INC

Report period: 24 May 2021
Transactions: 2
Transaction value: -$1,885
Accepted by SEC: 01 Jun 2021, 17:39
Role: CEO Specialty Renal Products
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .